Healthcare Market Research Companies: How to Choose the Right Partner in 2026

The global healthcare outsourcing market stood at $381.5 billion in 2024 and is projected to reach $998.5 billion by 2034, growing at a 10.1% CAGR, according to Market.us research.

As pharmaceutical companies, medical device manufacturers, health plans, and providers face mounting pressure to make faster, evidence-backed decisions, the quality of your research partner increasingly determines whether you anticipate market shifts or react to them. Picking the wrong firm means budget committed to data that doesn’t connect to decisions, research that arrives too late to influence strategy, and compliance exposure from operationally thin programs.

This guide examines 10 healthcare market research and data intelligence companies, comparing their capabilities, compliance infrastructure, and ideal use cases to help you choose the right partner in 2026.

Top 10 Healthcare Market Research Companies for 2026: Comparison

#1 Helpware CX

The operational research backbone for healthcare organizations

What separates Helpware CX from every other company on this list isn’t a proprietary database or a syndicated survey platform. It’s the human infrastructure that makes healthcare research programs work in practice. Founded in 2015 and headquartered in Lexington, Kentucky, Helpware CX delivers healthcare BPO services that include HIPAA-compliant patient outreach, data operations, quality monitoring, and clinical operations support across 19 locations in 11 countries. For life sciences companies and health systems that need reliable, compliant data collection to underpin their market intelligence programs, Helpware provides the operational layer that pure analytics firms can’t.

What that looks like operationally: the team manages patient and provider engagement across multiple channels, validates and cleans structured data from EHR and CRM platforms, handles prior authorization and eligibility inquiries that feed into population health analytics, and supports custom research programs with dedicated, trained agent teams. All of this runs under SOC 2, HIPAA, ISO 27001, and GDPR compliance frameworks with 100% call monitoring and documented quality protocols across every delivery center.

The metrics matter here. Helpware CX maintains a 90% CSAT score and a 2.8% monthly attrition rate, well below the 6-8% industry average, which means the team executing your research program actually stays long enough to develop genuine expertise in your therapeutic area or payer workflow. Partnerships average 5+ years, which reflects this consistency. When you’re running longitudinal patient engagement studies or ongoing payer research programs, staff continuity isn’t a nice-to-have. It’s critical. What also distinguishes Helpware is the data operations infrastructure behind the CX layer, including AI data annotation, clinical data labeling, and structured data workflows that increasingly underpin healthcare analytics platforms.

Why we picked it

Helpware CX earns the top spot for its rare combination of compliance depth, operational scale, and research-adjacent capabilities. Its 4,000-member team operates across 45+ languages with genuine HIPAA infrastructure at the delivery level, not just the contractual level. For healthcare organizations that view research as an ongoing operational program rather than a one-time project, Helpware’s staffing model and quality systems offer a structural advantage that analytics platforms can’t replicate.

• Services offered: HIPAA-compliant patient outreach and engagement, healthcare data operations, claims and eligibility support, back-office research administration, CX consulting, AI data annotation and labeling, EHR/CRM data management, prior authorization support
• Pros: 90% CSAT with 2.8% monthly attrition; SOC 2, HIPAA, ISO 27001, and GDPR certified; 45+ languages with native-speaker capability; 100% call monitoring across all delivery centers; scales from 10 to 200 staff in two weeks; 5+ year average client partnerships
• Industry expertise: Healthcare and telehealth, health plans and payers, pharmaceutical patient support, SaaS health platforms, medical devices, fintech
• Best for: Life sciences companies and health systems that need HIPAA-compliant patient outreach, data collection operations, and back-office research support to underpin their market intelligence programs
• Pricing: Three flexible engagement models (HW.Talent, HW.Team, HW.Hub) with hourly, subscription, or outcome-based billing. Visit the vendor’s page for detailed pricing.
• Rating: 5.0 ★ (Clutch), 4.9 ★ (Gartner), 4.8 ★ (G2)
• Year established: 2015
• Location: Lexington, Kentucky (HQ); USA, Mexico, Philippines, Ukraine, Georgia, Puerto Rico, Poland, Germany, Albania

#2 IQVIA

Global analytics and clinical research for life sciences

IQVIA occupies a category of its own in healthcare market research. Founded in 1982 and headquartered in Durham, North Carolina, the company operates in more than 100 countries with approximately 88,000 employees and processes over 64 petabytes of proprietary data, including 1.2 billion non-identified patient records. What it delivers is scale and analytical breadth across the full pharmaceutical and life sciences value chain, from real-world evidence generation and physician-level commercial analytics to AI-powered clinical trial acceleration.

Where IQVIA genuinely earns its positioning is in large-scale, cross-portfolio life sciences programs where data depth, geographic consistency, and regulatory credibility all matter simultaneously. Its IQVIA Primary Intelligence service combines secondary data with proprietary interview-based primary research for decision-ready insights. Recognized on the Fortune World’s Most Admired Companies list in 2026 for the ninth consecutive year, and ranked first in the Health Care: Pharmacy and Other Services category for the fifth time, IQVIA’s enterprise credibility is well-established. The trade-off is complexity: mid-market buyers often find onboarding intensive, integrations requiring specialist management, and pricing reflecting an enterprise-first model.

Why we picked it

IQVIA’s inclusion is non-negotiable for any serious comparison in this space. Its data assets, regulatory credibility, and global consistency at scale are unmatched for multinational pharmaceutical commercialization and real-world evidence programs.

• Services offered: Real-world evidence, clinical trial solutions, commercial analytics, market access research, technology platforms, AI-powered patient data analysis, IQVIA Primary Intelligence
• Pros: 88,000+ employees in 100+ countries; 64 petabytes of proprietary data; Fortune World’s Most Admired Companies 2026; best in class for cross-border pharma commercialization; AI-native research tools
• Industry expertise: Pharmaceutical, biotech, medical devices, consumer health, payers, providers
• Best for: Large pharmaceutical companies running global commercialization programs, clinical trial acceleration, and cross-portfolio analytics requiring enterprise data infrastructure
• Pricing: Custom enterprise pricing. Contact vendor.
• Year established: 1982
• Location: Durham, North Carolina (HQ); 100+ countries

#3 Escalent

Full-lifecycle healthcare and life sciences research

Escalent has been doing market research for more than 40 years, and the healthcare and life sciences practice reflects that depth. Founded in 1975 and headquartered in Livonia, Michigan, the company operates with approximately 1,200 employees across 9 locations spanning North America, Europe, and Asia-Pacific. Its healthcare practice supports pharmaceutical, biotech, and medical device clients from pre-clinical discovery through post-launch tracking, combining primary research, behavioral science, and secondary data into integrated advisory programs.

Where Escalent stands out is patient journey mapping. The team uses a proprietary methodology combining ethnographic qualitative work with quantitative segmentation to surface insights that standard survey programs miss. Its 2023 acquisitions of C Space and Hall & Partners added consumer co-creation and qualitative research depth, making it a fuller end-to-end partner for organizations navigating personalized medicine and patient-centric clinical design. The ISO/IEC 27001 certification signals genuine data security maturity for regulated healthcare clients. That said, Escalent covers many sectors beyond healthcare, which means dedicated healthcare bench strength varies by practice and region.

Why we picked it

Escalent earns its spot for the quality of its primary research methodology in life sciences and the unusual depth of patient experience work it brings to brand strategy and launch planning.

• Services offered: Qualitative and quantitative market research, patient journey mapping, brand strategy, competitive intelligence, segmentation, behavioral science application, product development research
• Pros: 40+ years of market research experience; strong patient journey methodology; ISO/IEC 27001 certified; C Space and Hall & Partners acquisitions added co-creation capability; full product lifecycle coverage
• Industry expertise: Pharmaceuticals, biotech, medical devices, healthcare services
• Best for: Life sciences companies needing primary research-driven insights for product launch, brand strategy, and patient-centric program design
• Pricing: Custom project-based pricing. Contact vendor.
• Year established: 1975
• Location: Livonia, Michigan (HQ); USA, UK, Europe, APAC

#4 M3 Global Research

The world’s largest physician panel for healthcare fieldwork

There’s one thing M3 Global Research does better than anyone else: access to verified healthcare professionals at scale. Part of M3 Inc., founded in 2000 and listed on the Tokyo Stock Exchange (joining the NIKKEI 225 in 2019), M3 operates a physician panel covering more than 2 million verified healthcare professionals across 27 countries. Its ISO 20252 certification for the physician panel and ISO 27001 for information security reflect a commitment to data quality that matters especially when research conclusions influence clinical or market access decisions.

M3’s core value is fieldwork speed and respondent quality. The company handles quantitative surveys, qualitative depth interviews, and online community research, with panel turnaround available in as little as 48 hours through its Agile service. PwC conducts the annual audit, providing an external validation of panel quality that few competitors can match. For organizations running primary research programs that depend on hard-to-reach specialties, including oncology, rare diseases, and hematology, M3’s panel depth and incentive infrastructure consistently outperform generalist research platforms. The limitation is scope: M3 is primarily a fieldwork and data collection partner rather than a full strategic research consultancy.

• Services offered: Physician panel surveys, qualitative depth interviews, patient and caregiver research, online communities, global data analytics and reporting, agile 48-hour fielding
• Pros: 2M+ verified healthcare professionals in 27 countries; ISO 20252 and ISO 27001 certified; PwC-audited annually; 48-hour Agile fielding available; strong specialty depth in oncology and rare diseases
• Industry expertise: Pharmaceutical, biotech, medical devices, health systems
• Best for: Organizations that need fast, high-quality access to verified HCP respondents for quantitative surveys or qualitative research across multiple markets
• Pricing: Project-based pricing. Contact vendor.
• Year established: 2000
• Location: Fort Washington, Pennsylvania (HQ); USA, UK, Sweden, Australia, Japan, India, South Korea, China

#5 Definitive Healthcare

SaaS-based commercial intelligence for healthcare go-to-market teams

Definitive Healthcare takes a different approach to healthcare market research. Founded in 2011 by Jason Krantz in Framingham, Massachusetts, the company built a SaaS platform that aggregates data on over 9,300 hospitals and integrated delivery networks, 2.6 million physicians, nurses, and allied health professionals, and claims-level utilization across the US healthcare market. It went public on the Nasdaq in 2021 and has approximately 900 employees serving biopharma, medtech, software, and professional services clients.

What makes Definitive Healthcare useful is specificity. It’s built for commercial teams that need to identify which hospital systems are adopting a specific device, which physicians prescribe a target treatment most frequently, or which markets are growing in a particular specialty. The platform’s Carevoyance solution handles medtech commercial targeting; Monocl handles expert and KOL identification; Populi covers population health analytics. For go-to-market planning and territory design, the platform replaces weeks of manual research with self-service query. The trade-off is coverage: Definitive Healthcare is deeply US-focused, and its 2025 annual revenue declined year-over-year to $241.5 million, which raises legitimate questions about platform investment pace going forward.

• Services offered: Hospital and provider data, physician and HCP profiles, claims analytics, market sizing, go-to-market planning tools, KOL identification, territory intelligence
• Pros: Over 9,300 hospital and IDN profiles; 2.6M+ HCP records; purpose-built for commercial healthcare teams; SaaS model enables self-service query; Databricks Healthcare Partner of the Year 2024
• Industry expertise: Biopharma, medical devices, healthcare IT, professional services, staffing
• Best for: Commercial teams in biopharma and medtech that need provider-level targeting intelligence, territory planning, and account prioritization in the US market
• Pricing: SaaS subscription model. Contact vendor for current pricing.
• Year established: 2011
• Location: Framingham, Massachusetts (HQ); USA and international

#6 Komodo Health

AI-powered real-world patient data and healthcare intelligence

Komodo Health takes real-world evidence to a different level of technical ambition. Founded in 2014 by Arif Nathoo and Web Sun in New York, the company has raised $514 million in funding from investors including a16z and Tiger Global, and built the Healthcare Map, a de-identified longitudinal dataset covering more than 330 million US patients with 16 million clinical encounters added daily. In 2025, Komodo launched Marmot, a proprietary AI engine designed to compress healthcare insight generation from weeks to minutes.

What Komodo delivers is speed and scale for real-world evidence generation. Life sciences organizations use the Healthcare Map for trial design, commercial launch strategy, patient identification, and post-market evidence programs. The AI layer allows commercial teams to query complex patient journey questions without requiring specialist data scientists for every analysis. For organizations prioritizing AI-native workflows in their research operations, Komodo represents the leading edge of where healthcare intelligence is heading. The trade-off is that the platform is US-centric, primary qualitative research isn’t its strength, and the cost structure reflects a venture-backed enterprise model.

• Services offered: Real-world patient data analytics, patient journey mapping, trial design intelligence, commercial launch strategy, AI-powered claims analytics, market access evidence generation
• Pros: 330M+ patient records; 16M daily clinical encounter updates; Marmot AI engine for rapid insights; $514M in venture funding; a16z and Tiger Global-backed; strong for evidence generation at scale
• Industry expertise: Life sciences, biopharma, medical devices, payers
• Best for: Life sciences organizations that need fast, scalable real-world evidence and AI-powered patient journey analytics in the US market
• Pricing: Enterprise licensing. Contact vendor.
• Year established: 2014
• Location: New York, New York (HQ); Chicago and San Francisco

#7 Ipsos Healthcare

Global reach and multi-methodology research for healthcare brands

Ipsos is the world’s third-largest market research firm, founded in Paris in 1975 and now operating in 87 countries with approximately 20,000 employees. Its Healthcare division handles brand tracking, payer research, patient and caregiver surveys, physician studies, and communications testing for pharmaceutical, biotech, and medtech clients across all major markets. Total group revenues reached approximately €2,525 million in 2025.

Ipsos Healthcare’s geographic reach is its primary differentiator. For multinational brands running parallel research programs across Europe, the US, Asia-Pacific, and emerging markets, Ipsos can operate with methodological consistency and local panel access that smaller regional firms cannot match. Its data practices carry ISO certification and ARF awards, which matters in regulated healthcare environments where research integrity faces external scrutiny. The limitation is that Ipsos is a generalist research firm at its core, and healthcare depth in specific therapeutic areas or rare disease segments may fall short of specialists like Escalent or M3 Global Research.

• Services offered: Brand health tracking, payer and formulary research, physician and patient surveys, market access studies, communications pre-testing, competitive intelligence, global multi-market studies
• Pros: 87-country footprint; 20,000+ employees; ISO-certified data practices; AI-driven multi-source analytics; methodological consistency across geographies; strong payer and HCP research capabilities
• Industry expertise: Pharmaceutical, biotech, consumer health, medical devices
• Best for: Global pharmaceutical or medtech brands needing consistent cross-market research programs with reliable local panel access across multiple regions simultaneously
• Pricing: Project-based pricing. Contact vendor.
• Year established: 1975
• Location: Paris, France (HQ); 87 countries

#8 Cerner Enviza

Oncology and rare disease research with real-world evidence depth

Cerner Enviza began as Kantar Health, established in 2009 and acquired by Cerner Corporation in April 2021. The company has more than 600 employees across the US, UK, Europe, and Asia-Pacific, with a particular focus on oncology and rare diseases. Its research is cited in more than 400 peer-reviewed journals, reflecting genuine scientific credibility rather than just commercial research credentials.

The company’s National Health and Wellness Survey, covering 12 countries, is one of the largest patient-reported outcomes databases available to life sciences researchers. Its CancerMPact database, a detailed oncology patient journey and treatment pattern platform, is used by 16 of the top 20 global pharmaceutical companies. Where Cerner Enviza earns its differentiation is in integrated real-world evidence: linking claims, electronic health records, and patient-reported outcomes for analytical depth that claims-only platforms can’t match. For rare disease or oncology research where sample size limitations challenge traditional survey approaches, the firm’s data fusion methodology is genuinely sophisticated.

• Services offered: Patient-reported outcomes research, real-world evidence, oncology data analytics, rare disease research, brand and market access studies, epidemiology databases
• Pros: 400+ peer-reviewed journal citations; National Health and Wellness Survey covers 12 countries; CancerMPact used by 16 of top 20 pharma companies; strong integrated claims and PRO methodology
• Industry expertise: Oncology, rare diseases, pharmaceutical, biotech
• Best for: Life sciences companies focused on oncology or rare disease that need peer-reviewable real-world evidence and integrated patient-reported outcomes research
• Pricing: Custom project-based pricing. Contact vendor.
• Year established: 2009 (as Kantar Health; rebranded 2021)
• Location: New York, New York (HQ); USA, UK, Europe, APAC

#9 GlobalData

Broad healthcare intelligence for strategic planning and competitive monitoring

GlobalData covers healthcare broadly rather than deeply. The company operates a unified intelligence platform integrating pharmaceutical pipeline data, clinical trial analytics, competitive benchmarking, epidemiology, and market forecasting across pharma, biotech, and medtech sectors. Its analyst-written commentary and trend reports give clients a fast-scan view of market dynamics without commissioning custom research programs. For organizations needing to quickly orient strategic planning teams around a new therapeutic area or track competitor pipeline activities across multiple disease areas, GlobalData’s breadth is genuinely efficient.

What GlobalData does less well is granular primary research or methodology-specific deep dives. The platform is designed for coverage and orientation, not for the validated primary work that regulatory submissions or formulary access strategies require. That said, its integration of company financials, trial data, and market analytics in a single platform gives strategy teams a real productivity advantage for continuous competitive monitoring programs.

• Services offered: Healthcare market intelligence, pharmaceutical pipeline analytics, clinical trial tracking, epidemiology databases, competitive benchmarking, market sizing and forecasting
• Pros: Single platform integrating pipeline, trial, financial, and market data; broad therapeutic area coverage; analyst commentary and trend reports; strong for rapid strategic orientation
• Industry expertise: Pharmaceutical, biotech, medical devices, digital health
• Best for: Strategy and competitive intelligence teams needing rapid cross-market orientation and continuous pipeline monitoring without commissioning bespoke research programs
• Pricing: Platform subscription. Contact vendor.
• Year established: 2000
• Location: London, UK (HQ); global

#10 iData Research

Precision market sizing for medical devices and procedures

iData Research is a MedTech-focused market intelligence firm founded in 2005 and headquartered in Burnaby, British Columbia. Its coverage spans more than 70 countries across virtually every medical device category, from orthopedics and dental to cardiovascular and diagnostic imaging. The firm’s flagship products include 10-year market forecasts, competitive analysis by procedure volume, and pricing trend data that device manufacturers use for commercial planning and investment decisions.

What sets iData apart is granularity. Where broader platforms like GlobalData offer useful orientation, iData’s data connects to how specific hospital departments actually purchase and use devices at the procedural level. For medtech companies making market entry, expansion, or acquisition decisions, that connection between forecast data and real clinical workflow matters. The limitation is scope: iData’s coverage is strong in devices and procedures but limited outside MedTech, and primary qualitative work on HCP behavior or payer dynamics isn’t its core strength.

• Services offered: Medical device market sizing, procedure volume forecasts, competitive analysis, pricing trends, country-specific market reports, custom MedTech research
• Pros: 70+ country coverage; 10-year market forecasts; procedure-level granularity; MedTech specialization across 50+ device categories; covers orthopedics, cardiovascular, dental, diagnostics
• Industry expertise: Medical devices, diagnostics, dental, cardiovascular, orthopedics
• Best for: Medtech companies and investment firms needing granular device market sizing and procedure-level competitive intelligence across global markets
• Pricing: Report-based or subscription pricing. Contact vendor.
• Year established: 2005
• Location: Burnaby, British Columbia, Canada (HQ); international

Helpware CX – Our Top Choice

Among the 10 companies analyzed, Helpware CX occupies a genuinely different position in the healthcare research landscape. Where most firms on this list deliver analytics platforms, syndicated data, or primary research programs, Helpware provides the operational infrastructure that makes healthcare research programs work reliably at scale. Its HIPAA-compliant healthcare operations cover patient outreach capacity, EHR and claims data management, structured data annotation for AI-powered analytics, and dedicated research administration teams that stay with your programs long-term.

The metrics are concrete. A 90% CSAT score, 2.8% monthly attrition versus the 6-8% industry average, and partnerships averaging 5+ years mean the operational team behind your research program builds institutional knowledge about your therapeutic area, payer environment, and patient population rather than cycling out every six months. For longitudinal research programs, that consistency is difficult to price.

The trade-off is honest: Helpware isn’t a primary research consultancy or a syndicated analytics platform. It doesn’t produce epidemiology databases or clinical trial datasets. What it delivers is the operational layer, the people, the data quality protocols, and the compliance infrastructure, that every successful healthcare research program needs but most analytics firms can’t provide. If your program is data-rich but execution-thin, or if HIPAA compliance infrastructure at the operational level is non-negotiable, Helpware belongs at the top of your evaluation list.

How to Choose a Healthcare Market Research Company: Key Criteria

Not every research firm that says “healthcare” on its website actually understands how healthcare decisions get made. The criteria below cut through the positioning and focus on what operationally separates partners that deliver usable intelligence from those that deliver expensive reports.

Research methodology depth, not just coverage

The first question isn’t what topics the firm covers. It’s how. A firm that runs physician surveys should be able to explain its respondent verification protocol, its approach to controlling survey fatigue in specialist panels, and how it handles low-incidence populations in rare disease. A platform that aggregates claims data should document how records are linked across payers and de-identified without introducing selection bias. Breadth of coverage is easy to claim. Methodological rigor is harder to fake when you ask specific questions about it.

Compliance infrastructure at the operational level

HIPAA compliance in a vendor contract and HIPAA compliance in daily operations are different things. What matters is how compliance functions at the level of the people handling your data and engaging your patient or provider populations. Ask how frequently staff complete HIPAA refresher training, what PHI access controls exist at the agent level, whether the firm has had reportable breaches, and how data handling agreements are audited over the engagement lifecycle. SOC 2 Type II, ISO 27001, and GDPR certifications with third-party audit are the meaningful signals here, not self-attestation.

Therapeutic area familiarity, not general healthcare experience

A firm with “extensive healthcare experience” may have done hundreds of primary care studies and nothing in hematology. Ask for case studies from the same therapeutic area or comparable patient population. Request a conversation with the team members who would actually run your program. The right research partner asks substantive questions about your clinical context, your payer environment, and your target populations before discussing methodology. A firm that leads with timeline and price before understanding your science is telling you something important about how they approach work.

Panel quality and respondent access for your specific population

For primary research, the quality of the panel is the quality of the research. Verify that respondents are independently verified, not self-reported. Ask about response rates and survey completion quality in your specific specialty or patient segment. For rare disease or highly specialized physician audiences, ask how the firm handles panels where the qualifying population is small. A firm like M3 Global Research that maintains ISO 20252 certification and PwC-audited panel quality is making a structural commitment that generalist panels often don’t.

Turnaround speed aligned to your decision cycle

Research that arrives after the decision window has closed has no value regardless of quality. Understand the firm’s standard delivery timeline for your methodology type and whether it has the flexibility to accelerate. For some programs, 48-hour agile fielding matters. For others, a 12-week longitudinal study is exactly what the question requires. Misalignment between research timelines and internal decision cycles is one of the most common reasons research budgets go to waste.

Reporting quality and decision readiness

Data is not insight. The firms that earn long-term partnerships consistently deliver findings in formats that accelerate decisions, not just documents that summarize what respondents said. Ask to see a sample output from a comparable engagement. Look for evidence that the firm draws implications and recommends actions, not just tabulates responses. Executives making market access, launch, or competitive positioning decisions need research that says “here’s what this means and here’s what to do,” not a 200-slide deck that documents every subgroup breakdown.

Ongoing support versus project delivery

Decide whether you need a transaction or a relationship. If your research needs are episodic and well-defined, project-based pricing from a specialized firm may serve you well. If your program involves longitudinal patient engagement, continuous competitive monitoring, or an operational research infrastructure that needs to adapt as your market evolves, look for a partner with the staffing model and institutional flexibility to stay with you over time. Five-year average partnership tenure, as with Helpware CX, reflects an operating model that’s built for continuity rather than volume.

The Right Partner is the One That Fits Your Actual Research Program

Healthcare market research in 2026 looks nothing like it did five years ago. AI-powered patient data platforms, real-time claims analytics, and longitudinal real-world evidence programs have raised the ceiling for what’s possible. What hasn’t changed is the risk of choosing the wrong partner: budget committed to data that doesn’t connect to decisions, compliance exposure from operationally thin programs, and insights that arrive too late to influence strategy. No provider on this list is right for every healthcare organization. The decision should start with what your program actually needs, whether that’s primary or secondary data, analytics platforms or operational execution, global scale or therapeutic specialization. The companies that consistently deliver the most research value are those that ask the hard questions about your clinical context, payer landscape, and decision timeline before they start. Start there.